Raloxifene augmentation in men and women with a schizophrenia spectrum disorder: A study protocol

B.A. Brand*, J.N. de Boer, S.B.J.O. Ophuis, M.I.E. Slot, B. De Wilde, K.C.E.E.R. Catthoor, A.J. Goverde, P.R. Bakker, M.C. Marcelis, K.P. Grootens, J.J. Luykx, S.M. Heringa, C.S. Weickert, I.E.C. Sommer, T.W. Weickert

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Web of Science)
Original languageEnglish
Article number100681
Number of pages8
JournalContemporary Clinical Trials Communications
Volume20
DOIs
Publication statusPublished - 1 Dec 2020

Keywords

  • antipsychotic medication
  • cognition
  • double-blind
  • estrogen
  • negative syndrome
  • performance
  • persistent symptoms
  • postmenopausal women
  • raloxifene
  • randomised controlled trial
  • reliability
  • scale
  • schizophrenia
  • sex-differences
  • PERFORMANCE
  • Estrogen
  • Schizophrenia
  • RELIABILITY
  • SCALE
  • POSTMENOPAUSAL WOMEN
  • PERSISTENT SYMPTOMS
  • NEGATIVE SYNDROME
  • COGNITION
  • Antipsychotic medication
  • Randomised controlled trial
  • DOUBLE-BLIND
  • ESTROGEN
  • Raloxifene
  • SEX-DIFFERENCES

Cite this